Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[January, 2008]
|
| In: |
Haematologica, the hematology journal
Year: 2008, Jahrgang: 93, Heft: 1, Pages: 124-127 |
| ISSN: | 1592-8721 |
| DOI: | 10.3324/haematol.11644 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3324/haematol.11644 Verlag, lizenzpflichtig, Volltext: https://haematologica.org/article/view/4696 |
| Verfasserangaben: | Henk M. Lokhorst, Ingo Schmidt-Wolf, Pieter Sonneveld, Bronno van der Holt, Hans Martin, Rene Barge, Uta Bertsch, Jana Schlenzka, Gerard M. J. Bos, Sandra Croockewit, Sonja Zweegman, Iris Breitkreutz, Peter Joosten, Christof Scheid, Marinus van Marwijk-Kooy, Hans-Juergen Salwender, Marinus H. J. van Oers, Ron Schaafsma, Ralph Naumann, Harm Sinnige, Igor Blau, Michel Delforge, Okke de Weerdt, Pierre Wijermans, Shulamiet Wittebol, Ulrich Duersen, Edo Vellenga, and Hartmut Goldschmidt for Dutch-Belgian HOVON and German GMMG |
| Zusammenfassung: | In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p |
|---|---|
| Beschreibung: | Gesehen am 21.01.2022 |
| Beschreibung: | Online Resource |
| ISSN: | 1592-8721 |
| DOI: | 10.3324/haematol.11644 |